ANIK - NASDAQ
Anika Therapeutics, Inc.
$14.41
+0.49%Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
At a Glance
Live SnapshotAnika Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Capital-intensive growth: Heavy reinvestment limits current cash available but may drive future returns. Assess whether CapEx supports compelling growth opportunities with adequate ROI.
Anika Therapeutics, Inc. Cash Flow Statement
ANIK • NASDAQ
| Anika Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-10.9M | -56.4M | -82.7M | -14.9M | 4.1M | -24M | 27.2M | 18.7M | 31.8M | 32.5M | 30.8M | 38.3M | 20.6M | 11.8M | 8.5M | 4.3M | 3.7M | 3.6M | 6M | 4.6M | |
5.7M | 8.1M | 14.2M | 14.5M | 14.3M | 15M | 6M | 5.9M | 4.3M | 3.7M | 3.8M | 4.7M | 4.8M | 4.5M | 4M | 3.3M | 1.3M | 1.4M | 818.7K | 384.1K | |
-7K | 260K | -6.3M | -5.3M | -1.8M | -3.5M | 794K | -1.8M | -1.2M | -712K | -1.6M | -8.8M | 1.3M | -462.7K | 1.7M | 1.9M | 1.7M | 377K | 696.5K | 660K | |
10.1M | 13.1M | 15.2M | 14.3M | 11.1M | 0.0 | 6.1M | 11M | 5.8M | 3.4M | 2.2M | 1.6M | 1.3M | 1.2M | 1.2M | 1.1M | 958K | 1.4M | 911.7M | 1.3B | |
7.1M | 53.4M | 69.9M | 7.6M | -4.7M | 39.1M | 3.6M | 4.3M | 2.5M | 706K | 945K | 377.8K | 122.3K | 3.1M | 1.8M | 1M | 322.9K | -117.9K | -911.3M | -1.3B | |
(0.0) | (4M) | (3.1M) | (106K) | (1.2M) | (0.0) | (9.3M) | (5.6M) | (15.1M) | (22.8M) | (12.7M) | (13.8M) | (9.8M) | (6.5M) | (2.7M) | (360K) | (1.2M) | (10K) | (1.8M) | (0.0) | |
-823K | -13.1M | -12.1M | -11.8M | -14.7M | -13.5M | -6.6M | -3.2M | -2.4M | -15.9M | 3M | 3.8M | -2.9M | -9.5M | -7M | -3.8M | -4.9M | -3.3M | -3.5M | -4.5M | |
11.2M | 5.4M | -1.8M | 4.4M | 8.4M | 13.1M | 37M | 34.9M | 40.8M | 23.8M | 39.1M | 40M | 25.2M | 10.5M | 10.2M | 7.9M | 3.1M | 3.4M | 4.5M | 2M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-6.8M | -7.7M | -5.4M | -7.5M | -5.1M | -1.6M | -2.8M | -4.7M | -9M | -14M | -9.2M | -1.6M | -440.9K | -1.5M | -1.4M | -2.8M | -4M | -16.2M | -14.8M | -1.3M | |
(9M) | (0.0) | (0.0) | (0.0) | -476K | -94.6M | -42.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -16.3M | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -20M | -103.8M | -91.6M | -45M | -39.2M | -45.3M | -26.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.5M | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 2.5M | 45M | 146.4M | 46M | 41.5M | 46.5M | 24.3M | 20M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5M | 0.0 | 0.0 | |
-2.6M | -600K | 0.0 | 0.0 | 0.0 | 0.0 | 42.5M | -45.6M | -3.5M | 7.3M | -21M | -6.8M | 187.7K | 0.0 | 0.0 | 105.3K | 0.0 | -58.1K | -1B | 0.0 | |
-401K | -8.3M | -5.4M | -7.5M | -3.1M | -71.3M | (39.7M) | -50.3M | -12.5M | -6.8M | -30.2M | -8.3M | -253.2K | -1.5M | -1.4M | -2.7M | -20.2M | -12.8M | -18.3M | -1.3M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-9M | -10.9M | -5M | 0.0 | 0.0 | 1.5M | -30M | -30M | 0.0 | -25M | 0.0 | 2.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9M | 1.2M | |
0.0 | 0.0 | 0.0 | -284K | -201K | -558K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.6M | -1.6M | -1.6M | -1.6M | -1.6M | 15.9M | 0.0 | 0.0 | |
-9.5M | -10.9M | -5M | (0.0) | (0.0) | (0.0) | -30M | -30M | (0.0) | -25M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (16.8B) | (0.0) | (0.0) | (0.0) | |
-1.6M | -1.8M | -1.3M | -4.6M | -6.6M | -4.7M | 22.2M | 1.1M | 314K | 1.7M | 1.9M | 3.3M | 3.9M | 841.1K | 434.7K | 262.7K | -43.5K | 775.1K | 643.4K | 505.9K | |
-10.6M | -12.7M | -6.3M | -4.9M | -6.8M | -3.8M | -8.1M | -28.9M | 314K | -23.3M | 1.9M | 5.3M | -5.7M | -758.9K | -1.2M | -1.3M | -1.6M | 16.7M | 2.5M | 1.7M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
86K | -48K | 79K | -130K | 69K | 327K | -133K | 29K | 349K | -138K | -208K | -184.6K | 43.1K | 5.1K | -32.2K | -61.5K | 0.0 | 0.0 | 0.0 | 0.0 | |
322K | -15.7M | -13.5M | -8.1M | -1.4M | -61.6M | 68.4M | -44.2M | 29M | -6.4M | 10.6M | 36.8M | 19.3M | 8.3M | 7.6M | 3.8M | -18.8M | 7.3M | -11.3M | 2.4M | |
57.2M | 72.9M | 86.3M | 94.4M | 95.8M | 157.5M | 89M | 133.3M | 104.3M | 110.7M | 100.2M | 63.3M | 44.1M | 35.8M | 28.2M | 24.4M | 43.2M | 35.9M | 47.2M | 44.7M | |
57.5M | 57.2M | 72.9M | 86.3M | 94.4M | 95.8M | 157.5M | 89M | 133.3M | 104.3M | 110.7M | 100.2M | 63.3M | 44.1M | 35.8M | 28.2M | 24.4M | 43.2M | 35.9M | 47.2M | |
4.4M | -2.3M | -7.2M | -3.1M | 3.3M | 11.4M | 34.2M | 30.3M | 31.8M | 9.8M | 29.8M | 38.4M | 24.7M | 9M | 8.8M | 5.1M | -867.5K | -12.8M | -10.3M | 695.4K |
SEC Filings
ANIK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 24, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | July 30, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 30, 2025 | July 30, 2025 | 2025 |
Related Guides
Continue your ANIK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.